MENU
Home
Add Document
Sign In
Create An Account
PDF Reader
Full Text
correspondence
tion is the more probable explanation. The addition of a 2-week regimen of gentamicin to a 4-week regimen of penicillin or ceftriaxone is not warranted for the treatment of penicillin-sensitive (minimal inhibitory concentration,
Suggest Documents
Combining retinoic acid and oral arsenic may be potentially the first-line therapy for non-high-risk acute promyelocytic leukemia.
Erratum: Retinoic acid and arsenic trioxide in the treatment of acute promyelocytic leukemia: current perspectives [Corrigendum].
The "retinoic acid syndrome" in acute promyelocytic leukemia.
Novel retinoic acid receptor-alpha transcripts in acute promyelocytic leukemia responsive to all-trans-retinoic acid.
Acute promyelocytic leukemia with isochromosome 17q and cryptic PML-RARA successfully treated with all-trans retinoic acid and arsenic trioxide.
All-Trans Retinoic Acid plus Arsenic Trioxide versus All-Trans Retinoic Acid plus Chemotherapy for Newly Diagnosed Acute Promyelocytic Leukemia: A Meta-Analysis.
All-trans retinoic acid and arsenic trioxide fail to derepress the monocytic differentiation driver Irf8 in acute promyelocytic leukemia cells.
Cost-Effectiveness Analysis of Treating Acute Promyelocytic Leukemia Patients With Arsenic Trioxide and Retinoic Acid in the United States.
Outpatient oral treatment for acute promyelocytic leukemia.
Randomized phase III trial of retinoic acid and arsenic trioxide versus retinoic acid and chemotherapy in patients with acute promyelocytic leukemia: health-related quality-of-life outcomes.
Incidence of secondary neoplasms in patients with acute promyelocytic leukemia treated with all-trans retinoic acid plus chemotherapy or with all-trans retinoic acid plus arsenic trioxide.
Retinoic acid in acute promyelocytic leukemia: a model for differentiation therapy.
retinoic acid receptor alpha.
ASCORBIC ACID - MODULATION OF ARSENIC TRIOXIDE TOXICITY: IMPLICATION FOR THE CLINICAL TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA.
Diagnostic immunophenotype of acute promyelocytic leukemia before and early during therapy with all-trans retinoic acid.
Metabolism of arsenic trioxide in acute promyelocytic leukemia cells.
Resistance to arsenic therapy in acute promyelocytic leukemia.
Selenite promotes all-trans retinoic acid-induced maturation of acute promyelocytic leukemia cells.
Lingual ulceration associated with retinoic acid syndrome during treatment of acute promyelocytic leukemia.
All-trans-retinoic acid-induced pseudotumor cerebri in acute promyelocytic leukemia.
All-trans retinoic acid in acute promyelocytic leukemia: preliminary results in Cuba.
All-trans retinoic acid (ATRA) therapeutical effect in acute promyelocytic leukemia.
Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid).
Pregnancy-induced hypertension caused by all-trans retinoic acid treatment in acute promyelocytic leukemia.
Oral arsenic and retinoic acid for non-high-risk acute promyelocytic leukemia.
Oral arsenic and retinoic acid for non-high-risk acute promyelocytic leukemia. - PDF Download Free
435KB Sizes
1 Downloads
7 Views
Download PDF
Recommend Documents
Combining retinoic acid and oral arsenic may be potentially the first-line therapy for non-high-risk acute promyelocytic leukemia.
Erratum: Retinoic acid and arsenic trioxide in the treatment of acute promyelocytic leukemia: current perspectives [Corrigendum].
The "retinoic acid syndrome" in acute promyelocytic leukemia.
Novel retinoic acid receptor-alpha transcripts in acute promyelocytic leukemia responsive to all-trans-retinoic acid.
Acute promyelocytic leukemia with isochromosome 17q and cryptic PML-RARA successfully treated with all-trans retinoic acid and arsenic trioxide.
All-Trans Retinoic Acid plus Arsenic Trioxide versus All-Trans Retinoic Acid plus Chemotherapy for Newly Diagnosed Acute Promyelocytic Leukemia: A Meta-Analysis.
All-trans retinoic acid and arsenic trioxide fail to derepress the monocytic differentiation driver Irf8 in acute promyelocytic leukemia cells.
Cost-Effectiveness Analysis of Treating Acute Promyelocytic Leukemia Patients With Arsenic Trioxide and Retinoic Acid in the United States.
Outpatient oral treatment for acute promyelocytic leukemia.
Randomized phase III trial of retinoic acid and arsenic trioxide versus retinoic acid and chemotherapy in patients with acute promyelocytic leukemia: health-related quality-of-life outcomes.
×
Sign In
Login with Facebook
Don't have an account?
Forgot Password?
×
Sign Up
By clicking register, I agree to your terms